Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Other Non-Current Assets for 10 consecutive years, with $10.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Assets rose 32.2% year-over-year to $10.8 million; the trailing twelve-month figure through Jun 2026 stood at $10.8 million (up 32.2% YoY), and the FY2025 full-year result was $11.3 million, up 9.62% from the prior year.
• Other Non-Current Assets fell to $10.8 million in Q2 2026 per KNSA's latest filing, from $11.2 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $11.3 million in Q4 2025 and bottomed at $827000.0 in Q4 2023.
• Historically, Other Non-Current Assets has averaged $6.6 million across 5 years, with a median of $6.9 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets slumped 85.8% in 2023, then jumped 1147.28% in 2024.
• Over 5 years, Other Non-Current Assets stood at $5.8 million in 2022, then plunged by 85.8% to $827000.0 in 2023, then surged by 1147.28% to $10.3 million in 2024, then rose by 9.62% to $11.3 million in 2025, then dropped by 4.18% to $10.8 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $10.8 million, $11.2 million, and $11.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.